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Abstract Objective: To assess the 
effect of a long-acting inhaled fl2- 
agonist, salmeterol (SM), compared 
to a short-acting inhaled fl2-agonist, 
salbutamol (or albuterol, SB), on 
the occurrence of morning dip (MD)  
in patients recovering from an acute 
severe asthma attack (ASA).  
Design: Prospective study 
Setting: 18-bed, medical intensive 
care unit (ICU) in a university hos- 
pital. 
Patients: 19 patients uffering f rom 
an ASA. 
Interventions: Serial measurements  
of the peak expiratory flow rate 
(PEFR),  arterial b lood gases, vital 
capacity and forced expiratory vol- 
ume in one second (FEVI) were 
performed from admission. All pa- 
tients were first t reated with i.v. me- 
thyl prednisolone and i.v. SB. Once 
the PEFR was stable and > 35 % of 
predicted value, i.v. SB was stopped 
while i.v. steroids were maintained, 
and patients were randomised to ei- 
ther inhaled SB (9 patients, 400 ~tg 
every 4 h) or inhaled SM (10 pa- 
tients, 100 ~tg every 12 h). 
Results: The mean admission PEFR 
was 26.1 + 11.7 % of the predicted 
value and was not dif ferent between 
the two groups. MD was more  fre- 
quent with SB (6/9 patients) than 
with SM (4/10). The severity of MD, 
expressed in 1/min fall in PEFR,  was 
higher in SB than in SM (106 + 25 vs 
55 + 37; p < 0.05). 
Discussion: MD is f requent  in ASA.  
In ASA,  SM appears to reduce the 
frequency and the severity of  MD 
more than SB. The clinical implica- 
tions of this observation, particular- 
ly a lowering of mortal i ty and a 
shortening of the ICU stay, remain 
to be investigated. 
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Introduction 
Nocturnal symptoms and worsening of asthma at the 
end of the night are common features in asthma patients 
[1-3]. The nadir of the peak expiratory flow rate 
(PEFR)  at this time is called morning dip (MD) [4]. At  
the present ime, the cause(s) of this nocturnal worsen- 
ing is unknown. Although a circadian rhythm of changes 
in airway calibre is observed in normal persons, the 
range of these changes is much greater in patients with 
asthma [5, 6]. There are probably several coexisting fac- 
tors, including vagal tone [7], body temperature [8], al- 
lergens [9] and a variation of hormones [10] favouring 
and/or causing this airway instability. Fur thermore,  in 
the hospital, respiratory arrests due to asthma, some- 
times leading to death, are more common at the end of 
the night [11-13] and probably correspond to the MD 
observed at this time. 
Until recently, the available inhaled bronchodi lators,  
due to their  short half-life, could not cover the full 8 h 
of a normal  night's sleep, so that many studies on noctur- 
nal asthma were conducted with oral theophyl l ine or 
oral sustained slow-release fl2-agonists. Though these 
treatments are sometimes effective in reducing noctur- 
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nal symptoms,  many  pat ients cannot  to lerate therapeu- 
t ically ef fect ive doses [14-17]. Sa lmetero l  (SM), a new 
inhaled fl2-agonist, differs f rom convent iona l  fl2-mimetic 
drugs in that  it p roduces  bronchod i la ta t ion  f r  up to 
12 h after  a single inhaled dose [18, 19]. This may be 
due to the long l ipophil ic side cha in  that permits  persis- 
tent  b ind ing and repeated  st imulat ion at the f l -adreno- 
ceptor  site. Sa lmetero l  is ef fect ive in increasing the 
morn ing  PEFR value and in reduc ing  the nocturnal  
symptoms in pat ients with chron ic  stable asthma [20- 
23], but,  as far as we know, has never  been  tested in pa- 
t ients recover ing  f rom an ep isode of  acute severe asth- 
ma in an intensive care unit. 
The aim of  our  study was to compare  the effect of in- 
ha led SM, a long-act ing/32-agonist ,  with that  of  inhaled 
sa lbutamol  (SB) (or a lbuterol ) ,  a short -act ing fl2-ago- 
nist, on  the preva lence and intensity of  MD in patients 
recover ing  f rom an acute as thma attack,  since a de- 
crease in or  abol i t ion of  the MD might  reduce mortal i ty 
for  such patients. 
Patients and methods 
Patients were admitted into the medical intensive care unit (ICU) 
for an acute severe asthma ttack, defined as a PEFR of less than 
35 % of the predicted value and blood gases showing hypoxaemia 
with either normocapnia or hypercapnia. The present prospective 
study was approved by the Ethical Committee of the University 
Hospital of Geneva and all patients gave informed consent, except 
the patient who was intubated, for whom consent was obtained 
from next of kin. 
According to a standard treatment policy in our institution, all 
patients were treated with supplemental oxygen by face mask, i.v. 
prednisolone (Ultracorten H; 3-5 mg/kg per day given in six daily 
doses) and i.v. SB (= albuterol, Ventolin; 5-30 Ixg/min). Once the 
blood gas values were normalized and the PEFR was > 35 % of 
the predicted value and stable (i. e., showing less than 10 % vari- 
ability, defined as the difference between the highest and the 
lowest values ofPEFR, divided by the lowest value times 100) dur- 
ing the day and during the night, the i.v. SB was withdrawn and 
nebulization of SB with decreasing doses over 8 h were instituted 
(2.5 mg at 8 a.m., 1.25 mg at 12 a.m., 1.25 mg at 4 p.m.). The pa- 
tients were then randomly assigned either to inhaled SM (Sere- 
vent), 4 inhalations of 25 ~tg twice daily, or inhaled SB 2 inhalations 
of 200 ~xg six times a day, given by a metered-dose inhaler connec- 
ted to a spacer (Volumatic). The i.v. prednisolone was held con- 
stant throughout the study at the same dose as at admission (3- 
5 mg/kg), and the use of theophylline or ipratropium bromide was 
not allowed. Antibiotic therapy was prescribed by the attending 
staff if necessary. 
PEFR was measured every 2 h during 24 h from the end of the 
i.v. SB administration, by using a Wright peak flow gauge. The 
forced expired volume in 1 s (FEV1) and the forced vital capacity 
(FVC) were measured every 4 h with a portable spirometer (Micro 
Medical, Rochester, England). The highest value among three at- 
tempts for each measurement was recorded. Samples for arterial 
blood gases were drawn from the arterial ine at the same time as 
the PEFR measurement was made. MD was defined as a differ- 
ence of more than 15 % in PEFR between the highest diurnal read- 
ing and the 4 a.m. reading from the first night after randomization 
was conducted [2, 4]. No supplementary treatment was instituted 
during the study. 
Statistical comparison of the prevalence of MD between the 
two treatment groups was performed using a chi-square test, or 
Fisher's exact est, when appropriate. The fall in PEFR, age, dura- 
tion of asthma, height and weight of both groups were compared 
using an unpaired Student's t-test. The heart rate, respiratory rate, 
blood pressure and blood gas results were compared using a paired 
Student's t-test. All p values were based on two-sided tests, and a p 
value of 0.05 or less was considered to indicate statistical signifi- 
cance. The StatView II Abacus Concept statistical package for the 
Apple Macintosh was used. 
Results 
Nineteen asthmat ic  pat ients took  part in the study, 9 in 
the SB group and 10 in the SM group. On ly  1 pat ient 
was intubated and required mechanica l  vent i lat ion for 
12 h (SB group).  There  were no dropouts.  The charac- 
teristics of  all the pat ients are given in Table 1. Both  
t reatment  groups were similar with respect to all vari- 
ables. Table 2 gives the pat ients '  characterist ics just be- 
fore randomisat ion  to the SB or SM group. As  on admis- 
sion, no di f ference between the two groups could be 
found at this t ime. Table 3 shows the results of  the pul- 
monary  funct ion tests. Pat ients in the SB group  suffered 
a higher preva lence of  MD (6/9 vs 4/10). MDs  were also 
worse, i.e., deeper  in the SB groups as expressed either 
in 1/min fall in PEFR or in percentage decrease in 
PEFR (106_+25 vs 55 +_ 371/min and 37.5+_9.4 vs 
23.4 +6.4%,  cf. Table 3). F igure 1 shows the PEFR 
values during the night in the patients present ing a 
MD. At  midnight  and 2 a.m.,  both  groups showed a 
slight fall in PEFR,  while at 4 a.m. the SB group  exhib- 
ited a larger dip. A f te r  the MDs,  PEFRs  improved  in 
both groups, the 8 a.m. record ing being close to the 
highest diurnal value of  the preceding day. The FEV 1 
and FVC results were not  interpretable:  indeed,  most  
patients could not  produce  sufficiently long expirat ion 
through the sp i rometer  wi thout  exper iencing bouts of  
intense coughing,  a common f inding after a severe asth- 
ma attack. Nevertheless,  PEFR measurements  were re- 
liable because of  the short exhalat ion t ime needed for 
the measurement  recorded  v ry early in the expirat ion 
phase. 
Table 4 shows some of the haemodynamic  and b lood 
gas measurements  at the t ime of the best diurnal  PEFR 
and at the t ime of  the MD. There  was a signif icant in- 
crease in the part ial  pressure of  carbon dioxide in arter- 
ial b lood (PaCO2) and a decrease in pH dur ing the 
MD, though the magn i tude  of  the change was small. 
Nei ther  oxygenat ion,  assessed by the PaO]F IO2 in ratio 
between the part ial  pressure of  oxygen in arterial  b lood 
and fract ional  inspired oxygen,  nor  heart  rate nor  b lood 
pressure was di f ferent dur ing the MD. There was no cor- 
relat ion between the increase in PaCO 2 and the fall in 
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Table 1 Patients' general char- 
acteristics at admission. Values 
are mean + SD or numbers 
(PEFR peak expiratory flow 
rate, pHa arterial pH, PaCOe, 
PaO e partial pressure of carbon 
dioxide and of oxygen in arte- 
rial blood, FIO 2 fractional in- 
spired oxygen, BEa arterial 
base excess) 
Salbutamol Salmeterol pa 
Number of patients 
Sex (F/M) 
Age (years) 
Height (cm) 
Weight (kg) 
Duration of asthma (years) 
History of nocturnal asthma symptoms 
Atopic status 
Previous history of acute severe asthma 
Regular use of inhaled flz-mimetics 
Regular use of inhaled steroids 
PEFR at admission (% predicted value) 
pHa at admission 
PaCO 2 at admission (kPa) 
PaOJFIO2 at admission (kPa) 
BEa at admission (mEq/1) 
9 10 
7/2 6/4 
44.3 _+ 22.8 36.7 + 16.3 NS 
164 + 10 169 + 15 NS 
64.6 + 12.6 71.3 ± 34.8 NS 
18.2 ± 18.0 14.3 _+ 11.4 NS 
3 4 
3 4 
2 3 
7 7 
4 5 
28.6 + 11.6 25.4 _+ 12.1 NS 
7.29 + 0.13 7.36 ± 0.06 NS 
7.06 + 2.9 6.63 _+ 0.85 NS 
37.5 _+ 8.5 36.5 _+ 5.5 NS 
-2.6 ± 4.3 -2.1 ± 3.4 NS 
Student's t-test 
Salbutamol Salmeterol pa 
Table 2 Patients" characteris- 
tics at the time of random±sa- 
t±on. Values are mean + SD Time from admission into ICU 
to random±sat±on (h) 21.1 + 25.0 19.9 _+ 12.0 NS a 
Need for mechanical ventilation 
before random±sat±on (n) 1 0 NS b 
PEFR (% predicted value) 55 + 12 46 + 21 NS a 
PEFR variability under i.v. SB (%) 6 + 2 5 + 3 NS a 
pHa 7.40 + 0.06 7.40 + 0.04 NS a 
PaCO 2 (kPa) 4.3 + 0.3 4.5 _+ 0.6 NS a 
PaO2/FIO2 (kPa/FIOJ 40 + 8 34 + 7 NS a 
BEa (mEq/1) -2.6 + 4.3 -2.1 + 3.4 NS a 
a Student's t-test 
b Chi-square test 
Salbutamol Salmeterol p 
Number of MDs/number of patients 6/9 4/10 NS a 
Maximal PEFR fall (1/min) 106 + 25 55 + 37 < 0.05 b 
Maximal PEFR fall (%) 37.5 + 9.4 23.4 + 6.4 < 0.05 b 
Table 3 Characteristics of 
morning dips (MDs) 
Fall in PEFR indicates the difference in PEFR between the highest diurnal value and the 4 a.m. re- 
cording 
a Fisher's exact-test 
b Student's t-test 
PEFR dur ing the MD nor  between the fall in pH and in 
PEFR.  There  were  no d i f fe rence  in haemodynamics  or 
b lood gases between the SB and SM groups. 
Discussion 
In this study, we demonst ra ted  that inha led SM, 100 Ixg 
twice daily, compared  with inha led SB 400 ~tg six t imes 
a day, p roduced  a bet ter  cont ro l led ,  i .e. a more  stable,  
PEFR dur ing  the  n ight  in pat ients  recover ing  f rom an 
acute severe  as thma attack.  
SM has a l ready  been  compared  to SB, a shor t -ac t ing  
fl2-agonist, in pat ients  wi th stable chron ic  as thma [20-  
23]. SM produced  an increase  in the FEV 1 over  12 h 
and in the morn ing  PEFR,  as wel l  as a decrease  in the  
number  of  n ights of  d i s turbed  s leep and an improve-  
ment  in the qua l i ty  o f  s leep, assessed by e lec t roencepha-  
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Fig.1 Nocturnal peak expiratory flow rate PEFR, expressed as a 
percentage of the highest diurnal value (0)  recorded uring the 
day preceding the night shown on the graph. * p < 0.05 
lography. In our study, we investigated the effects of in- 
haled SM or SB in ICU patients recovering f rom an 
acute severe asthma attack, a clinical situation in which, 
as far as we know, no previous information exists on the 
comparat ive ff icacy of both agents. 
Several methodologica l  points of our study should be 
clarified. 
First, the dose of  SM that we used, 100 btg twice a day, 
was higher than the 50 Ixg twice a day usually recom- 
mended. This is due to the fact that most studies have 
been conducted on chronic stable asthmatic patients. 
The patients we have investigated were just recovering 
f rom an acute severe asthma crisis. Moreover,  the switch 
f rom i.v. SB to the inhaled fl2-mimetic was done in a 
short per iod of t ime, so that we decided to conduct our 
study with the maximal  recommended oses. This was 
done - as requested by our  Ethical Commit tee  - in or- 
der to avoid an abrupt  deter iorat ion of the asthma con- 
trol. Despite the fact that Bennett  et al. [24] have re- 
cently demonst rated that the systemic effects of inhaled 
SM on heart  rate and blood pressure were 'more  impor- 
tant than the effects of inhaled SB, we did not notice 
any difference in the heart  rate, respiratory rate or 
blood pressure between the SM or SB groups during 
the night, suggesting that both t reatment  regimens 
were probably  equipotent.  
Second, because every pat ient did not inhale the fl2- 
mimetic at exactly the same t ime of the day, we cannot 
exclude that the effects of SM or SB could have been 
different due to different imes of administration. How- 
ever, the diurnal and nocturnal  PEFR profiles were 
quite similar within groups of "morning dippers", on ei- 
ther SB or SM, whereas the magnitude of the MDs were 
different, as shown in Fig. 1, between the two groups of 
patients when considered by the treatment option. Fur- 
thermore, MD, as defined, occurred effectively at 
around 4 a.m. (4.2 _ 0.8 h a.m., mean + SD). In addi- 
tion, although we did not assess the subjective tolerance 
to SM or SB, no pat ient in either group needed a rescue 
treatment during the study because of worsening asth- 
ma. All this suggests that the t ime of administration of 
the drugs, provided that the duration of action of the 
medication is accounted for, is not essential for stabiliz- 
ing the airway tone in patients recovering from an at- 
tack of acute severe asthma. 
Other  authors have already published data on asth- 
ma and long-acting fl2-mimetics. Rabe et al. [25] investi- 
gated the effects of formotero l  and SM on airway re- 
sponsiveness over  24 h in mildly asthmatic patients, by 
measuring the FEV1 every 4 h. Both drugs were supe- 
rior to placebo in control l ing the airway tone, but a cir- 
cadian rhythm of airway tone and responsiveness, with 
a worsening of the FEV 1 at 4.30 a.m., was still detect- 
able. In our study, 6/9 pat ients in the SB and 4/10 pa- 
tients in the SM group developed an MD, despite ag- 
gressive anti-asthmatic medicat ion,  although the magni- 
tude of the fall in PEFR was less important in the SM 
group. This may indicate that the better airway stability 
of SM compared to SB is predominant ly  due to the long- 
er stimulation of the f lz-adrenoceptor f airway smooth 
muscle, but that there still exists a circadian rhythm of 
airway inf lammation. This airway tone instability is not 
control led by fl2-mimetics, despite the fact that SM has 
some ant i - inf lammatory propert ies  [26]. To support the 
role of inf lammation in nocturnal  asthma, recent studies 
have shown a decline of endothelin-1 and an increase in 
eosinophilic cationic protein and lymphocyte count in 
bronchoalveolar lavage fluid taken at 4 p.m. and 4 a. m. 
[27, 28]. These findings do not prove that these inflam- 
matory  changes indeed cause nocturnal asthma, but 
Table 4 Haemodynamic and 
blood gas values in patients 
presenting a morning dip (com- 
parison between the parame- 
ters recorded with the highest 
diurnal PEFR vs during MD) 
Highest diurnal PEFR Morning dip p 
Respiratory rate (breaths/min) 23 _+ 5 22 + 5 
Heart rate (beats/min) 87 _+ 13 78 + 13 
Systolic blood pressure (mmHg) 117 + 17 117 _+ 18 
Diastolic blood pressure (mm Hg) 62 + 9 62 + 9 
pHa 7.42 _+ 0.03 7.39 _+ 0.03 
PaCO 2 (kPa) 4.5 + 0.7 4.7 _+ 0.5 
BEa (mEq/1) -1.9 + 2.9 -2.2 __ 3.3 
PaO2/FIO2 (kPa/FIO2) 38 + 8 35 + 8 
a Student's t-test 
NS 
NS 
NS 
NS 
< 0.05 a 
0.05 a 
NS 
NS 
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they suggest a role for in f lammatory mediators in poten- 
tiating airway inf lammation. On the other hand, we can- 
not be sure that such an inf lammatory component  may 
have participated in the MD that we observed in our pa- 
tients, because we did not per form bronchoalveolar 
lavage while our patients received high doses of i. v. cor- 
ticosteroids. Furthermore,  autonomic nervous system 
activity affecting the airway narrowing in our patients 
cannot be excluded, as our patients did not receive ipra- 
t ropium bromide, which has been shown to reduce noc- 
turnal asthma [29]. 
We could not assess the effect of SM on morbidity 
(i. e. the length of stay in the ICU and/or other parame- 
ters) and mortal ity in our study due to the small number  
of patients. It is well known that a marked diurnal varia- 
tion in PEFR entails a heightened risk of asthma recur- 
rence, and, sometimes, of death, in the days following 
ICU discharge [13]. It is thus possible that the better sta- 
bility of the PEFR with SM may reduce mortality in pa- 
tients recovering from an acute severe asthma attack 
and discharged to the ward, but this remains to be stud- 
ied with larger numbers of patients. The high prevalence 
(52 %) of patients presenting an MD in our study indi- 
cates that a high proport ion of patients remains at risk 
after an acute severe asthma attack, despite subjective 
improvement  and normal izat ion of blood gases, and 
that serial assessment of the PEFR is still mandatory 
when managing such patients. 
Finally, another  potent ia l  benef it  of using SM instead 
of i.v. SB in these patients could be to reduce the costs 
of hospital ization. In our ICU, the mean length of stay 
for acute severe asthma patients is less than 4 days 
[1993-1996, 89 acute asthma patients; length of stay 
(mean + SD): 3.37 + 2.25 days]. The cost for 24-h treat- 
ment  with i.v. SB (5 ixg/min) is about  U. S. $ 40, whereas  
it amounts  to only around U. S. $ 3 for 200 ~tg of inhaled 
SM. Thus, the switch f rom SB to SM would only result 
in a small cost savings, unless t reatment  using SM could 
reduce the length of stay by al lowing the transfer of a 
patient,  once weaned f rom a cont inuous i. v. infusion, to 
an intermediate care unit, where aerosol  therapy could 
be more  easily undertaken.  
We conclude that in patients recover ing f rom an 
acute severe asthma attack inhaled SM 100 ~tg twice a 
day is more  effective than inhaled SB 400 ~tg six t imes 
a day in reducing the prevalence and intensity of MD 
as assessed by serial PEFR measurements .  This could 
reduce the mortal i ty  for such pat ients and shorten 
their ICU stay, but these points remain  to be investiga- 
ted in a larger populat ion. In addit ion, MD seems to 
be frequent,  when systematical ly looked for, in pa- 
tients recovering f rom an acute asthma attack in the 
ICU setting. 
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